Clinical trials: IPF
Idiopathic Pulmonary Fibrosis (IPF)
To Determine Safety and Tolerability of MG-S-2525 and to Evaluate Its PK Profile in Healthy Volunteers
This is a Phase I stage to investigate the safety and tolerability of MG-S-2525 in healthy volunteers. The proposed trial consists of 3 study parts to be conducted at Tri-Service General Hospital and includes Single Ascending…
- Trial name
- NCT03650075
- Testing
- MG-S-2525
- Where
- Taiwan
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Metagone Biotech Inc.
Lung Diseases, Interstitial
A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis
This study in China is open to people with progressive lung fibrosis (chronic fibrosing ILDs with progressive phenotype) who are at least 18 years old.
- Trial name
- NCT05065190
- Testing
- Nintedanib
- Where
- 16 sites in China
- Volunteers
- 81 people
- Sponsor
- Boehringer Ingelheim
Alveolitis Extrinsic Allergic, Pulmonary Fibrosis
Pirfenidone in the Chronic Hypersensitivity Pneumonitis Treatment
The Chronic Hypersensitivity Pneumonitis (HP), is an inflammatory disease who has an evolution to develop progressive interstitial fibrosis, who cause the death of the patient.
- Trial name
- Picheon (NCT02496182)
- Testing
- Pirfenidone
- Where
- Mexico
- Volunteers
- 60 people
- Sponsor
- Grupo Medifarma, S. A. de C. V.
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF)
The primary objective of this study is to evaluate the effect of 52 weeks of once daily treatment with TPIP compared with placebo on lung function in adults with PPF.
- Trial name
- PALM-PPF (NCT07805785)
- Testing
- Treprostinil Palmitil Inhalation Powder
- Volunteers
- 800 people
- Sponsor
- Insmed Incorporated
Idiopathic Pulmonary Fibrosis
Real-life-persistence to Antifibrotic Treatments
This study will help to better understand the persistence rate to antifibrotic (AF) treatment in real life in France and to identify potential areas for improvement by investigating the factors associated with a non-persistence…
- Trial name
- REPEAT (NCT06485635)
- Testing
- Nintedanib, Pirfenidone
- Where
- France
- Volunteers
- 10,646 people
- Sponsor
- Boehringer Ingelheim
Persistent Cough in IPF, Chronic Cough
A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF
Idiopathic pulmonary fibrosis (IPF) is a rare, progressive life-threatening disease that is characterized by exertional dyspnea and persistent dry cough.
- Conditions
- Persistent Cough in IPF, Chronic Cough, IPF
- Trial name
- SCENIC (NCT03864328)
- Testing
- RVT-1601
- Where
- 81 sites in United States, Australia and 9 more
- Volunteers
- 108 people
- Sponsor
- Respivant Sciences GmbH
Idiopathic Pulmonary Fibrosis
A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis
HZNP-HZN-825-303 (HARBOR) comprises of 2 parts. Part 1 (Core Phase) is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial to evaluate the efficacy, safety and tolerability of HZN-825 in participants…
- Trial name
- NCT05032066
- Testing
- HZN-825
- Where
- 82 sites in United States, Argentina and 17 more
- Volunteers
- 153 people
- Sponsor
- Amgen
Idiopathic Pulmonary Fibrosis
Adherence to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients
This is a non-interventional cohort study using existing administrative data from the U.S. Medicare program. This study has two objectives: Identification of adherence trajectories of nintedanib among Idiopathic Pulmonary…
- Trial name
- NCT05022784
- Testing
- Nintedanib
- Where
- United States
- Volunteers
- 1,798 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Study of ORJ-001 for the Treatment of IPF
ORJ-001 is a new class of drugs intended for the treatment of patients with idiopathic pulmonary fibrosis (IPF). This is a Phase 2 study in two parts; the objective of Part A will determine if ORJ-001 is well-tolerated by…
- Trial name
- NCT07869147
- Testing
- ORJ-001
- Where
- 2 sites in United States
- Volunteers
- 95 people
- Sponsor
- Oorja Bio, Inc.
Adjustment Disorder
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to…
- Trial name
- NCT07002034
- Testing
- RE104 for Injection
- Where
- 32 sites in United States
- Volunteers
- 100 people
- Sponsor
- Reunion Neuroscience Inc
Pulmonary Fibrosis
Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects
This study aims to evaluate the interaction of oral HRS-9813 capsules with pirfenidone and nintedanib on the pharmacokinetics of healthy subjects.
- Trial name
- NCT07229716
- Testing
- HRS-9813 Capsule, Nintedanib Soft Capsules, Pirfenidone Tablets
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.
- Conditions
- Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis
- Trial name
- TETON-OLE (NCT04905693)
- Testing
- Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer
- Where
- 192 sites in United States, Argentina and 16 more
- Volunteers
- 1,850 people
- Sponsor
- United Therapeutics
Idiopathic Pulmonary Fibrosis
Study To Investigate The Potential DDI Between HEC585 And Pirfenidone/Nintedanib In Healthy Subjects
A single-center, open-label study designed to assess the drug-drug interaction of HEC585 and pirfenidone in healthy male and female subjects.
- Trial name
- NCT07588646
- Testing
- HEC585, Nintedanib, Pirfenidone
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Idiopathic Pulmonary Fibrosis
A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
This study is open to adults with a lung disease called Idiopathic Pulmonary Fibrosis (IPF). People can join the study if they are 40 years or older.
- Trial name
- NCT05321069
- Testing
- BI 1015550
- Where
- 334 sites in United States, Argentina and 35 more
- Volunteers
- 1,177 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Post Marketing Surveillance of Nintedanib in Indian Patients With Idiopathic Pulmonary Fibrosis
This is an active surveillance study to monitor the real world safety of nintedanib in Indian patients with Idiopathic Pulmonary Fibrosis.
- Trial name
- NCT03047031
- Testing
- Nintedanib, Pirfenidone
- Where
- 8 sites in India
- Volunteers
- 21 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Fibrosis
Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF)
The purpose of this study is to determine whether NAC added to prednisone, and azathioprine has a better effect on lung function, radiology and clinical condition than placebo + prednisone in combination with azathioprine after 6…
- Trial name
- IFIGENIA (NCT00639496)
- Testing
- n-acetylcysteine
- Where
- 7 sites in Belgium, France and 5 more
- Volunteers
- 184 people
- Sponsor
- Zambon SpA
Idiopathic Pulmonary Fibrosis
A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
This is a randomized, multicenter, double-blind, placebo-controlled, parallel-group study of vismodegib in patients with IPF. Eligible patients will be randomized in a 2:1 ratio to one of two treatment arms: vismodegib or…
- Trial name
- NCT02168530
- Testing
- vismodegib
- Sponsor
- Hoffmann-La Roche
Idiopathic Pulmonary Fibrosis
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
- Trial name
- NCT06967805
- Testing
- MTX-463
- Where
- 59 sites in United States, Argentina and 9 more
- Volunteers
- 168 people
- Sponsor
- Mediar Therapeutics
Idiopathic Pulmonary Fibrosis
To Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy Volunteers
An open label study to evaluate drug-drug interactions between HEC585 and Pirfenidone or Nintedanib in healthy volunteers
- Trial name
- NCT05383131
- Testing
- HEC585, Pirfenidone, Nintedanib
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Idiopathic Pulmonary Fibrosis
Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
A multicenter randomized, double-blind, parallel group, placebo-controlled, exploratory phase IIa study in subjects with Idiopathic Pulmonary Fibrosis (IPF) to evaluate safety, tolerability, pharmacokinetics (PK), and…
- Trial name
- NCT02738801
- Testing
- GLPG1690 600 mg QD
- Where
- 8 sites in Ukraine, United Kingdom
- Volunteers
- 23 people
- Sponsor
- Lakefront Biotherapeutics NV